Gag recombinant epitope protein and application thereof

By developing a highly specific gag recombinant epitope protein kit, the problem of large-scale sample detection in OPA diagnosis is solved, efficient and accurate JSRV detection is achieved, batch diagnosis is supported and operation errors is reduced, and it is suitable for different technical levels. operator.

CN119019515APending Publication Date: 2024-11-26YULIN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411027042.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing OPA histopathological detection and PCR technology are difficult to achieve diagnostic and detection of large batches of samples, and there are problems such as complex operation, long time, high cost and insufficient results stability, which makes it difficult to achieve early diagnosis, affecting the purification of the sheep farm and The development of sheep farming industry.

Method used

A gag recombinant epitope protein with strong specificity, good repeatability and high sensitivity was developed to prepare a kit, and efficient detection of JSRV is achieved by coating with solid support or carrying detectable markers. Supports batch diagnosis and reduces operational errors.

Benefits of technology

The test compliance rate of 98% is achieved, which is suitable for clinical batch testing, which reduces errors among operators, and the results are more accurate and objective. It is suitable for operators of different technical levels, which significantly improves the specificity and sensitivity of JSRV detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019515A_ABST
    Figure CN119019515A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of virus detection, and particularly relates to gag recombinant epitope protein and application thereof. The invention provides a gag recombinant epitope protein. The amino acid sequence of the gag recombinant epitope protein is as follows: 1) the amino acid sequence is as shown in SEQ ID NO: 1; or 2) a derived amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence in 1), wherein the derived amino acid sequence has the activity of the amino acid sequence shown in 1). The gag recombinant epitope protein disclosed by the invention can be used for detecting the JSRV, and the kit for detecting the JSRV disclosed by the invention is excellent in performance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of virus detection, and in particular relates to a gag recombinant epitope protein and an application thereof. Background Art

[0002] Ovine pulmonary adenomatosis (OPA; Sheep pulmonary Adenomatosis, SPA) is a chronic, progressive, contact-transmitted lung tumor disease caused by Jaagsiekte sheep retrovirus (JSRV). It is characterized by progressive adenomatous hyperplasia of the alveolar and bronchial epithelium, cough, runny nose, weight loss, dyspnea, and ultimately death.

[0003] Epidemiological survey results show that OPA often presents with mixed typical and atypical features, and clinical diagnosis is difficult to detect. It is usually confirmed by finding corresponding lung tissue pathological changes through OPA histopathological detection methods after the sheep die or are slaughtered. In particular, no circulating antibodies or T lymphocyte responses against JSRV can be detected in sheep infected with OPA. Therefore, the early diagnosis of OPA-infected sheep can only be done through laboratory JSRV nucleic acid PCR (polymerase chain reaction) detection.

[0004] However, the samples for OPA histopathology testing are lung tissues of dead sheep, which is inconvenient to collect and has few sources. Moreover, it can only be performed after the sheep die or are slaughtered. The OPA detection and purification of sheep farm groups, the quarantine of introduced species, and the epidemiological investigation of OPA have no guiding significance for clinical safety production. PCR technology detection targets nucleic acids, including sampling, RNA extraction, reverse transcription, gene amplification and other links. There are many factors that affect the results, and there are shortcomings such as complex operation process, long time consumption, and high cost. Furthermore, both OPA histopathology and PCR technology detection have the defects of a small number of samples that can be tested at one time and cannot be used for batch diagnostic testing of a large number of clinical samples. For example, both OPA histopathology and PCR technology detection are single-sample operations, which are greatly affected by the technical level of the operator and other factors, and the stability of the results is insufficient.

[0005] Therefore, developing reagents or methods that can target pathogenic structural proteins and can be used for large-scale clinical testing will be able to effectively solve the problems existing in OPA diagnosis, achieve OPA purification in sheep farms, ensure the health of the flock, and promote the rapid development of the sheep industry. Summary of the invention

[0006] In order to improve the performance of JSRV detection reagents, the inventors studied the full-length gag protein and, through a large number of experiments, selected a gag recombinant epitope antigen from a variety of different truncated proteins that has strong specificity, good repeatability, high sensitivity, and meets the needs of immunodiagnostic reagent development, thereby completing the present invention.

[0007] In order to achieve the above object, the present invention provides the following technical solutions:

[0008] In a first aspect, the present invention provides a gag recombinant epitope protein, wherein the amino acid sequence of the gag recombinant epitope protein is:

[0009] 1) as shown in SEQ ID NO: 1; or

[0010] 2) A derivative amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence in 1), wherein the derivative amino acid sequence has the activity of the amino acid sequence shown in 1).

[0011] A second aspect provides a polynucleotide, wherein:

[0012] a) encoding the gag recombinant epitope protein according to claim 1;

[0013] b) as shown in SEQ ID NO:2; or

[0014] c) is complementary to a) or b).

[0015] In a third aspect, a polynucleotide construct is provided, wherein the polynucleotide construct contains the polynucleotide as described in the present invention.

[0016] In a fourth aspect, a host cell is provided, wherein the host cell contains the polynucleotide described in the present invention.

[0017] In a fifth aspect, a composition for detecting JSRV is provided, wherein the composition comprises the gag recombinant epitope protein as described in the present invention, wherein the gag recombinant epitope protein is coated on a solid support, or the gag recombinant epitope protein carries a detectable marker.

[0018] In a sixth aspect, a kit is provided, comprising the gag recombinant epitope protein described in the present invention.

[0019] Preferably,

[0020] 1) The gag recombinant epitope protein is coated on a solid support;

[0021] 2) the gag recombinant epitope protein carries a detectable marker; or

[0022] 3) The gag recombinant epitope protein is not coated on a solid support and does not carry a detectable marker.

[0023] A seventh aspect provides a kit for detecting JSRV, the kit comprising:

[0024] A solid support coated with a gag recombinant epitope protein,

[0025] Rabbit polyclonal antibody against gag recombinant epitope protein,

[0026] Anti-rabbit monoclonal antibody with detectable label.

[0027] In an eighth aspect, provided is the use of the gag recombinant epitope protein of the present invention in the preparation of a composition for detecting JSRV or a kit for detecting JSRV.

[0028] A ninth aspect provides use of the composition or kit of the present invention in detecting JSRV.

[0029] In the present invention, the quality of gag recombinant epitope protein (antigen) is the most critical factor affecting JSRV immune detection, so there is a continuous improvement in the performance of gag recombinant epitope protein (antigen) in the art to better enhance and meet the needs of JSRV in vitro detection capabilities. At the same time, since the antigens of viral infectious diseases are often large, it is difficult to express complete antigen proteins in vitro, or even if in vitro expression is achieved, antigen proteins with relatively large molecular weights often cannot be folded correctly, resulting in difficulty in later renaturation, or the antigen activity obtained by renaturation is very poor, which restricts the development of detection reagents.

[0030] To this end, the present invention provides a new gag recombinant epitope protein (antigen), which selects the 304-605aa region of the gag full-length protein. Such a recombinant antigen not only covers the dominant antigen epitope region of the gag recombinant epitope protein (antigen), but also has a detection ability that is superior to other antigens that are slightly different from the selected region, and has stronger specificity, better repeatability and higher sensitivity.

[0031] In the present invention, the derived recombinant antigen can have at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity with the amino acid sequence shown in SEQ ID NO:1.

[0032] The percent identity between amino acid (or nucleic acid) sequences can be determined using standard methods known to those skilled in the art. For example, in order to determine the percent identity between two amino acid sequences, the sequences are aligned to achieve the best comparison purpose. The amino acid residues at the corresponding amino acid positions are then compared. Rooms can be introduced in one or both amino acid sequences to achieve the best comparison, and non-homologous sequences can be ignored for the purpose of comparison. When the position in the first sequence is occupied by the same amino acid residue as the amino acid residue at the corresponding position of the second sequence, then at that position, the two sequences are identical. Taking into account the number of rooms introduced for the best comparison and the length of each room, the percent identity between the two sequences is a function of the number of identical positions shared by the two sequences. Sequence comparisons between the two sequences and percent identity and similarity can be determined using a mathematical algorithm.

[0033] The kit of the present invention can be in various forms well known to those skilled in the art, for example, test paper, test box containing various test reagents, microfluidic chip, etc., and the kit can be manufactured according to known standard procedures. For example, the kit of the present invention can be colloidal gold test paper. For example, the kit of the present invention can include a container, a chip, instructions for use, a buffer, an immunoadjuvant and / or other materials, structures and / or reagents required for diagnosis / detection as needed.

[0034] In the present invention, the gag recombinant epitope protein (antigen) of the present invention, when used to prepare a kit or composition, can be, for example, present in a dissolved or dried form in a container, coated on a solid support [for example, a membrane (such as an NC membrane), a plate, beads (such as magnetic beads), microspheres (such as carboxyl microspheres, amino microspheres, chloromethyl microspheres, physically adsorbed microspheres, etc.)], and present in a dissolved or dried form in a chamber of a chip, but the present invention is not limited thereto.

[0035] In the present invention, other reactants required for diagnosis / detection in the kit of the present invention include, but are not limited to, other gag antigens other than the gag recombinant epitope protein (antigen) of the present invention, etc. The above other reactants may be present in a conventional manner in the art, for example, in a dissolved or dried form in a container, coated on a solid support, or in a dissolved or dried form in a chamber of a chip, but the present invention is not limited thereto.

[0036] In the present invention, other materials required for detection in the kit of the present invention include but are not limited to materials for sampling, materials for comparison and / or materials for observing the detection process or results.

[0037] In the present invention, other reagents required for detection in the kit of the present invention include but are not limited to buffer, detergent, color developer and / or terminator.

[0038] In the present invention, the gag recombinant epitope protein (antigen) of the present invention is detectably labeled when used to prepare a kit or composition. Any marker and labeling method known to those skilled in the art can be used. Commonly used markers may include enzymes (such as horseradish peroxidase, β-galactosidase, alkaline phosphatase, etc.), radioisotopes (such as 32P or 125I), etc., biotin, digoxin, colloidal metals (such as colloidal gold, etc.), fluorescent dyes (such as fluorescein, rhodamine, Texas Red, etc.), chemiluminescent compounds or bioluminescent compounds (such as dioxetane, luminol or acridinium, etc.). Any well-known labeling steps in the art can be used, such as covalent coupling, iodination, phosphorylation, biotinylation, etc. of enzymes or biotin groups.

[0039] In the present invention, one or more of the other reactants required for detection may also be detectably labeled.

[0040] In the present invention, the present invention includes a method for detecting the presence of JSRV in a subject. For example, the detection method includes: contacting the sample of the subject with a solid support coated with the gag recombinant epitope protein (antigen) of the present invention, and then adding a specific antibody, so that the sample of the subject and the gag recombinant epitope protein (antigen) compete for binding to the specific antibody. Then add a second antibody with a detectable marker, bind it to the specific antibody, and form a second antibody-specific antibody-antigen complex with a detectable marker. Subsequently, the test result is obtained by measuring the detectable marker. The detection method includes but is not limited to ELISA (enzyme-linked immunosorbent assay), autoradiography, turbidimetry, fluorescence microscopy, direct and indirect enzymatic reaction, radioisotope method or non-radioisotope method, etc.

[0041] Preferably, a washing step is further included after the formation of the complex to remove unbound components.

[0042] In the present invention, the sample can be selected from the serum, chest cavity and nasal cavity secretions of living sheep and goats.

[0043] The present invention also relates to polynucleotides encoding gag recombinant epitope proteins (antigens), for example, to produce fusion proteins of recombinant antigens of the present invention. The polynucleotides encoding the gag recombinant epitope proteins (antigens) of the present invention include, but are not limited to: the coding sequence of the gag recombinant epitope protein (antigen) itself; the coding sequence of the gag recombinant epitope protein (antigen) and additional coding sequences; the coding sequence of the gag recombinant epitope protein (antigen) (and optional additional coding sequences) and non-coding sequences, for example, may further include but are not necessarily limited to one or more regulatory nucleic acid sequences, which may be regulated or regulatable promoters, enhancers, other transcriptional regulatory sequences, repressor binding sequences, translational regulatory sequences or any other regulatory nucleic acid sequences.

[0044] The present invention also includes equivalent polynucleotide constructs. It will be appreciated by those skilled in the art that polynucleotide constructs are used to prepare recombinant antigens by recombinant expression, and the polynucleotide constructs comprise nucleic acid molecules encoding recombinant antigens operably linked to expression control sequences, and additionally comprise genetic elements for maintaining and propagating in respective host cells, such as replication origins and / or selectable marker genes.

[0045] In the present invention, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies constituting the population are identical except for possible naturally occurring mutations that may be present in small amounts. Monoclonal antibodies are highly specific for a single antigenic site. Monoclonal antibodies are advantageous because they can be obtained by hybridoma cell line culture and are substantially free from contamination by other immunoglobulins.

[0046] In the present invention, the term "polymonoclonal antibody" refers to an immunoglobulin containing multiple different antigen epitopes. The antibody obtained by immunizing an animal with an antigen, producing an antibody in the animal, and obtaining an animal serum containing the antibody after preliminary purification is a polyclonal antibody. Polyclonal antibodies are mainly present in serum, and the serum obtained from the immunized animal is called antiserum or immune serum. This type of antiserum is a polyclonal antibody against multiple antigenic determinants on the antigen substance, and is a mixture of different types, subclasses and types of immunoglobulins.

[0047] Compared with the prior art, the beneficial effects of the present invention are:

[0048] The present invention optimizes the truncation position of the full-length gag protein and screens out the gag recombinant epitope protein from a variety of different truncated proteins, thereby preparing a kit with strong specificity, good repeatability, high sensitivity, and meeting the development needs of immunodiagnostic reagents. Moreover, the kit of the present invention and PCR technology were used for detection respectively, and the results showed that the conformity rate between the kit of the present invention and the PCR detection result was 98%, which met the use requirements of the in vitro diagnostic kit. Moreover, the detection procedure of the kit of the present invention is a batch operation, which can be suitable for clinical batch detection; it also reduces the operating errors between operators, and the results are more accurate and objective. Furthermore, the operating steps of the kit of the present invention are clear and standardized, and the judgment criteria are objective and accurate, which is suitable for technicians of different knowledge levels.

[0049] The serum antibody titer of the anti-gag recombinant epitope protein of the present invention is 12800 dilutions, and has a better immune effect.

[0050] The gag recombinant epitope protein of the present invention can be used in an ELISA kit for JSRV detection, can detect the pathogen JSRV of OPA, but cannot detect sheep brucellosis, sheep rapid disease, lamb dysentery, sheep enterotoxemia, sheep sudden death, sheep pox, peste des petits ruminants, O-type foot-and-mouth disease, sheep mycoplasma pneumonia and sheep endemic intranasal tumor virus (ENTV); it has good specific binding ability; in addition, the ELISA kit of the present invention that can be used for JSRV detection has good repeatability and high sensitivity.

[0051] On the one hand, the samples that can be detected by the present invention are serum, chest cavity and nasal cavity secretions of living sheep and goats, and sampling is convenient.

[0052] On the other hand, the present invention can detect JSRV in living sheep at any stage, and can be used for OPA detection and purification of sheep farm groups, introduction quarantine and OPA epidemiological investigation.

[0053] It is understandable that the existence of these properties greatly reduces the detection cost and use restrictions of JSRV. In other words, the present invention provides a gag recombinant epitope protein that can be used for in vitro diagnosis after systematic evaluation and has outstanding comprehensive capabilities. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] In order to more clearly illustrate the technical solution of the present invention, the drawings involved in the description of the embodiments will be briefly introduced below. Obviously, the drawings in the description are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0055] Figure 1 This is the electrophoresis diagram of gagw, envw, and gag3 genes;

[0056] Lane M in A represents 2000DL DNA Marker; Lanes 1 to 3 in A represent gag3 gene;

[0057] Lanes 1 to 4 in B represent the gagw gene; Lane M in B represents the 2000DL DNA Marker;

[0058] Lane 1-lane 2 in C represent envw gene; lane M in C represents 2000DL DNA Marker.

[0059] Figure 2 This is the double enzyme digestion electrophoresis diagram of gagw, envw, gag3, and pET-32a before ligation;

[0060] Lane M1 in A represents 2000DL DNA Marker; Lane 1 in A represents gag3;

[0061] Lane M1 in B represents 2000DL DNA Marker; Lanes 1 to 2 in B represent pET-32a; Lane 3 in B represents gagw; Lane 4 in B represents envw; Lane M2 in B represents 15000DL DNA Marker.

[0062] Figure 3 This is the double enzyme digestion electrophoresis diagram after the connection of gagw, envw, gag3, and pET-32a; among them,

[0063] Lane 1 in A represents pET-32a-gag3; Lane M1 in A represents 2000DL DNA Marker; Lane M2 in A represents 15000DL DNA Marker;

[0064] Lane M1 in B represents 2000DL DNA Marker; Lane M3 in B represents 5000DL DNA Marker; Lanes 1 to 3 in B represent pET-32a-gagw;

[0065] Lane M2 in C represents 15000DL DNA Marker; Lane M3 in C represents 5000DL DNA Marker; Lane 1 and Lane 2 in C represent pET-32a-envw.

[0066] Figure 4 This is a Western blot image of gag recombinant epitope protein (gag3p recombinant epitope protein). DETAILED DESCRIPTION

[0067] The technical scheme of the present invention is described below in conjunction with the embodiments, but the present invention is not limited to the following embodiments. The experimental methods and detection methods described in each embodiment are conventional methods unless otherwise specified; the reagents and materials described are all commercially available unless otherwise specified.

[0068] Example 1 Preparation of coated antigen, positive control and negative control

[0069] The coating antigen refers to the gag recombinant epitope protein (gag3p recombinant epitope protein) of JSRV virus used for coating the ELISA plate in the kit, the positive control refers to the gag full-length recombinant protein (gagp) of JSRV virus, and the negative control refers to the env full-length recombinant protein (envp) of JSRV virus.

[0070] in,

[0071] The term "gag recombinant epitope protein" in the specification is the same as the protein or amino acid sequence represented by the term "gag3p recombinant epitope protein";

[0072] The coating antigen, positive control and negative control were all expressed using a prokaryotic expression system, and the specific process is described as follows.

[0073] (I) Primer design and synthesis

[0074] Using the JSRV virus sequence (GenBank ID: AF105220) as a template, three pairs of primers were designed using Oligo7 software, as shown in Table 1 below.

[0075]

[0076] Note: The underlined lines are restriction enzyme cleavage sites.

[0077] (II) Extraction and reverse transcription of JSRV viral RNA

[0078] (1) Add 1 mL of PBS to the EP tube containing the nasal swab. After vortexing, take 200 μL of the sample solution to a 1.5 mL centrifuge tube (for RNA only), add 1.0 mL of RNAiso Plus, vortex thoroughly to mix, and let stand for 15 min.

[0079] (2) Add 200 μL of chloroform that has been pre-cooled on ice to the mixed liquid, vortex and let stand for 10 min, and centrifuge at 4°C and 12,000 rpm for 15 min.

[0080] (3) The liquid surface is divided into three layers. The supernatant is aspirated into a new 1.5 mL centrifuge tube (for RNA only). 500 μL of isopropanol is added and mixed by inversion. The tube is allowed to stand for 10 min and then centrifuged at 4°C and 12,000 rpm for 15 min.

[0081] (4) Discard the supernatant, add 1.0 mL of ethanol (diluted to 70% with DEPC water), and centrifuge at 4°C and 12,000 r / min for 10 min. Pour off the waste liquid, remove as much liquid as possible from the bottom, open the lid and let it air dry for 5 min, add 20.0 μL of DEPC-treated deionized water, and gently pipette to mix.

[0082] (5) According to the instructions of the reverse transcription kit Genecarer RT SuperMix with dsDNase, 13.0 μL of RNA was transferred to a PCR tube (for RNA only), 4.0 μL of 5× Reaction Mix and 3.0 μL of Supreme Enzyme Mix were added, and reverse transcribed into cDNA in a PCR instrument at 25°C for 10 min, 55°C for 10 min, and 85°C for 10 min.

[0083] (III) Cloning of gagw, envw, and gag3 epitope genes

[0084] A 50 μL PCR reaction system was established with PrimeSTAR Max Premix (2×), including 25.0 μL PrimeSTAR Max Premix (2×), 2.0 μL F and R primers, 4.0 μL cDNA, and 17.0 μL. PCR amplification was performed according to the following procedure, and the products were subjected to 1.5% agarose gel electrophoresis to obtain three products with the expected fragment size ( Figure 1 The gel was recovered using the Gel Extraction Kit (OMEGA, Cat: D2500-02) according to the kit instructions.

[0085]

[0086] (IV) Double digestion of pET-32a and target gene

[0087] The pET-32a plasmid and gagw, envw, gag3 gene gel extraction (Gel Extraction Kit, OMEGA, Cat: D2500-02) products were used to establish a double restriction enzyme system of BamHI, Xho or BamHI, HindⅢ, and the residues were analyzed by agarose gel electrophoresis ( Figure 2 ).

[0088] (1)10×Buffer 3.0μL(2) 10×Buffer 3.0μL(3) 10×Buffer 3.0μL

[0089] XhoⅠ / HindⅢ 1.5μL XhoⅠ 1.5μL HindⅢ 1.5μL

[0090] BamHI 1.5μL BamHI 1.5μL BamHI 1.5μL

[0091] pET-32a 24.0μL gag3 / gagw 33.0μL envw 33.0μL

[0092] (V) Connecting pET-32a with gagw, envw, and gag3 genes

[0093] The pET-32a plasmid and the three target gene digestion products were recovered by gel, and a ligation system was established with 5.5 μL of gagw / envw / gag3 digestion fragments, 1.5 μL of pET-32a plasmid, 1.0 μL of T4 ligase and 2 μL of Buffer (5 times ligation buffer), respectively. After mixing, the mixture was ligated in a 4°C refrigerator overnight.

[0094] (VI) Transformation and identification of recombinant plasmids

[0095] Add the above 10.0 μL ligation product to 100 μL DH5α competent cells, oscillate to mix, and quickly place on ice, ice bath for 30 minutes, and then heat shock in a 42°C water bath for 90 seconds, and immediately ice bath for 5 minutes, then add 700 μL, 37°C preheated LB liquid culture medium, 37°C, 200 r / min shaking culture for 60 minutes, the culture was centrifuged at 4000 r / min for 4 minutes, the supernatant was discarded, the precipitate was resuspended by blowing in the remaining approximately 100 μL liquid, and then spread on the Amp+ LB plate, and incubated upside down in a 37°C incubator for 12-16 hours, and single clone colonies were selected in 3.0 mL Amp+ LB liquid culture medium, and 37°C, 220 r / min shaking culture for 12-16 hours. The liquid culture was subjected to PCR identification of the recombinant plasmid according to the gene amplification procedure, and the gagw recombinant plasmid (comprising the nucleotide sequence shown in SEQ ID NO: 3), envw recombinant plasmid, and gag3 recombinant plasmid (comprising the nucleotide sequence shown in SEQ ID NO: 2) were extracted for double enzyme digestion identification ( Figure 3 ).

[0096] (VII) Expression of gagw, envw, and gag3 recombinant plasmids

[0097] The positive recombinant bacterial suspension was inoculated into 5.0 mL LB liquid medium (containing Amp+) and cultured on a shaker at 37°C for about 3 h. The absorbance (OD 600When the concentration of IPTG was 0.6, IPTG was added to the bacterial solution to make the final concentration reach 0.4 mmol / L, and the expression was induced for 5 h at 37 °C shaking incubator (150 r / min).

[0098] (VIII) Western blot identification of gagw, envw, and gag3p recombinant proteins

[0099] (1) Prepare the transfer solution in an ice bath in advance, cut a nitrocellulose (NC) membrane of the same size as the gel and soak it with thick filter paper.

[0100] (2) Transfer: After protein electrophoresis, place the soaked thick filter paper on the semi-dry transfer apparatus, and place the NC membrane, gel, and thick filter paper in the transfer splint in sequence. Cover the lid, keep a constant current of 80 mA, and perform semi-dry transfer for 2 hours.

[0101] (3) Blocking: Move the transferred NC membrane into a clean small box, add 5% skim milk, and block it on a shaker at room temperature at 50 rpm for 2 h.

[0102] (4) Pour off the blocking solution, add 10.0 mL of mouse anti-His monoclonal antibody (1:1000) diluted with 1% skim milk, and incubate overnight at 4°C and 50 rpm on a shaker.

[0103] (5) Wash the membrane 4 times with PBST, 5 min each time.

[0104] (6) Add 10.0 mL of 1% skim milk diluted goat anti-mouse-HRP (1:10000) and incubate at room temperature on a shaker (50 rpm) for 2 h.

[0105] (7) Wash the membrane four times with PBST, 5 min each time.

[0106] (8) Color development: ECL luminescent liquid was evenly added to the membrane, and finally an image was collected using a fully automatic chemiluminescence imaging analysis system to obtain gag3p (comprising the amino acid sequence shown in SEQ ID NO: 1) ( Figure 4 ), gagp (comprising the amino acid sequence shown in SEQ ID NO: 5) and envp (comprising the amino acid sequence shown in SEQ ID NO: 4).

[0107] Example 2 Preparation of rabbit polyclonal antibody against gag recombinant epitope protein (gag3p polyclonal antibody, primary antibody)

[0108] (I) Purification of recombinant gag3p epitope protein

[0109] Prepare separation gel and concentration gel according to the instructions of SDS-PAGE denaturing acrylamide gel rapid preparation kit (No. C631100-0200). Take 180μL of sample (gag3p recombinant epitope protein) and add 60μL of 4× loading buffer, a total of 240μL, mix well and put it into a water bath at 100℃ and boil for 5min. Use a 10μL pipette to add the treated sample solution from the top of the gel to the well; put the entire gel into the electrophoresis tank, add buffer, and perform electrophoresis at 80V constant voltage. When the sample moves to the separation gel, adjust the voltage to 100V, and stop electrophoresis when bromophenol blue is 2mm away from the edge of the gel; cut the gel of the size that meets the target protein and put it into a clean glass tissue grinder, add 4mL of PBS in an ice bath and grind; collect the grinding liquid, determine the protein concentration, and adjust the concentration to 1.0mg / mL.

[0110] (II) Animal Immunization

[0111] Rabbits were immunized with purified gag3p recombinant epitope protein as antigen at 0d, 14d, 28d, and 35d (Table 2). Blood was collected from the rabbit heart 3d (day) after the fourth immunization, and after coagulation, the blood was kept at 4°C overnight and centrifuged at 3000r / min for 4min to collect serum, which was the gag3p polyclonal antibody (gag3p-Mb), and was stored at -80°C for later use.

[0112] Table 2 Immunization schedule

[0113]

[0114] (III) Determination of gag3p-Mb titer by indirect ELISA

[0115] The steps are as follows:

[0116] Step 1: Add 5.0 μg / mL of gag3p recombinant epitope protein to the ELISA plate, 100 μL / well, shake and mix, and incubate at 4°C overnight.

[0117] Step 2: Pour away the liquid, wash the plate three times with 200 μL / well PBST, and spin dry.

[0118] Step 3: Add 5% skim milk (diluted with PBST), 200 μL / well, and incubate at room temperature for 1 h.

[0119] Step 4: Pour off the liquid, wash the plate three times with 200 μL / well PBST for each well, and spin dry.

[0120] Step 5. Add gradient dilutions of gag3p-Mb to each well, 100 μL / well. The concentrations of gag3p-Mb are 8.0 μg / mL, 4.0 μg / mL, 2.0 μg / mL, 1.0 μg / mL, 0.5 μg / mL, 0.25 μg / mL, 0.125 μg / mL, 0.0625 μg / mL and 0.03125 μg / mL, respectively. Incubate at 37°C for 1 h.

[0121] Step 6. Pour off the liquid, wash the plate three times with 200 μL / well PBST for each well, and spin dry.

[0122] Step 7: Add 1:50000 dilution (PBST dilution) of goat anti-rabbit IgG-HRP, 100 μL / well, and incubate at 37°C for 1 hour.

[0123] Pour off the liquid, wash the plate three times with 200 μL / well PBST for each well, and spin dry.

[0124] Add TMB substrate solution, 100 μL / well, seal the plate, and develop the color at room temperature in the dark for 15 min.

[0125] Add stop solution (2M H2SO4), 100 μL / well, and read OD with a microplate reader 450 nm value.

[0126] After calculation, the titer of gag3p-Mb is 12800 dilutions, i.e., 0.0625 μg / mL, indicating that the gag3p-Mb of the present invention has a good titer level.

[0127] (IV) Purification of polyclonal antibodies

[0128] gag3p-Mb was purified by the caprylic acid-saturated ammonium sulfate method, and the operation steps were as follows:

[0129] Step 1: Add 4 times the volume of gag3p-Mb into acetate solution and mix well.

[0130] Step 2: Use 0.2 mol / L NaOH to adjust the pH of the serum dilution solution to 4.5.

[0131] Step 3: Add caprylic acid dropwise with slow stirring on a magnetic stirrer at 4°C until the final concentration of caprylic acid reaches 75 μL / mL, and continue stirring at 4°C for 1 h.

[0132] Step 4: Centrifuge the serum mixture at 4°C and 10,000 rpm for 20 min.

[0133] Step 5: After the supernatant is filtered through a 0.45 μm filter, 10× PBS buffer is added at 10% of the volume.

[0134] Step 6: Adjust the pH to 7.4 with 2 mol / L NaOH and record the total volume.

[0135] Step 7: slowly add ammonium sulfate powder at 4°C while stirring until complete saturation (45%), and continue stirring at 4°C for 1 h.

[0136] Step eight, centrifuge the obtained liquid at 4°C and 10,000 r / min for 20 min, discard the supernatant, and collect the precipitate.

[0137] Step nine: Dissolve the precipitate with a small amount of PBS buffer (dialysis solution) containing 1 mM EDTA and dialyze at 4°C.

[0138] (V) Western blot of polyclonal antibodies

[0139] After SDS-PAGE electrophoresis, the gag3p recombinant epitope protein was transferred to a nitrocellulose membrane, and immunoblotting was performed using purified gag3p-Mb as the primary antibody and an enzyme-labeled secondary antibody as an anti-rabbit monoclonal antibody with a detectable marker. The gag3p-Mb prepared by the present invention can react specifically with the gag3p recombinant epitope protein. For detailed steps, see step (eight) in Example 1.

[0140] (VI) Determination of cross-reactions between gag3p recombinant epitope protein (antigen), blocking solution, primary antibody, and enzyme-labeled secondary antibody

[0141] (1) Is there a cross reaction between the antigen and the enzyme-labeled secondary antibody?

[0142] Step 1: Add 5 μg / mL purified gag3p recombinant epitope protein to the ELISA plate, 100 μL / well, and incubate overnight at 4°C.

[0143] Step 2: Pour away the liquid, wash the plate three times with 200 μL / well PBST, and spin dry.

[0144] Step 3: Add 1:50000 dilution (PBST dilution) of anti-rabbit monoclonal antibody with detectable marker, 100 μL / well, and incubate at 37° C. for 1 h.

[0145] Step 4: Pour off the liquid, wash the plate three times with 200 μL / well PBST for each well, and spin dry.

[0146] Step 5: Add TMB substrate solution, 100 μL / well, seal the plate, and develop the color at room temperature in the dark for 15 min.

[0147] Step 6: Add stop solution (2 mol / L H2SO4), 100 μL / well, and read OD with a microplate reader. 450 nm value.

[0148] After calculation, it was determined that there was no cross reaction between the antigen and the enzyme-labeled secondary antibody.

[0149] (2) Whether there is a cross reaction between the sample to be tested and the enzyme-labeled secondary antibody

[0150] Step 1: Add the sample to be tested to the ELISA plate, 100 μL / well, and incubate at 4°C overnight.

[0151] Step 2: Add 1:50000 dilution (PBST dilution) of anti-rabbit monoclonal antibody with detectable marker, 100 μL / well, and incubate at 37°C for 1 h.

[0152] Step 3: Pour away the liquid, wash the plate three times with 200 μL / well PBST, and spin dry.

[0153] Step 4: Add TMB substrate solution, 100 μL / well, seal the plate, and develop the color at room temperature in the dark for 15 min.

[0154] Step 5: Add stop solution (2 mol / L H2SO4), 100 μL / well, and read OD with a microplate reader. 450 nm value.

[0155] After calculation, there is no cross reaction between the sample to be tested and the enzyme-labeled secondary antibody.

[0156] (3) Is there a cross reaction between the blocking solution and the enzyme-labeled secondary antibody?

[0157] Step 1: Add PBS to ELISA plate, 100 μL / well, and incubate at 4°C overnight.

[0158] Step 2: Pour away the liquid, wash the plate three times with 200 μL / well PBST, and spin dry.

[0159] Step 3: Add 5% skim milk (diluted with PBST), 200 μL / well, and incubate at room temperature for 1 h.

[0160] Step 4: Add 1:50000 dilution (PBST dilution) of anti-rabbit monoclonal antibody with detectable marker, 100 μL / well, and incubate at 37° C. for 1 h.

[0161] Step 5: Pour away the liquid, wash the plate three times with 200 μL / well PBST, and spin dry.

[0162] Add TMB substrate solution, 100 μL / well, and develop color at room temperature in the dark for 15 min.

[0163] Add 100 μL / well of stop solution (2 mol / L H2SO4) and read OD with a microplate reader. 450 nm value.

[0164] According to calculation, there is no cross reaction between the blocking solution and the enzyme-labeled secondary antibody.

[0165] (VII) Determination of optimal antigen and antibody working concentrations

[0166] The optimal coating concentration of the protein and the optimal dilution multiple of the positive serum were determined by the square array method. The gag3 recombinant epitope protein was coated on an ELISA plate. Columns 1 to 7 of each plate were coated with gag3p recombinant epitope protein at concentrations of 40 μg / mL, 20 μg / mL, 10 μg / mL, 5 μg / mL, 2.5 μg / mL, 1 μg / mL and 0.5 μg / mL, respectively, and coated overnight at 4°C; the gag3p-Mb concentrations corresponding to rows 1 to 8 were 8.0 μg / mL, 4.0 μg / mL, 2.0 μg / mL, 1.6 μg / mL, 0.8 μg / mL, 0.4 μg / mL, 0.2 μg / mL and 0.1 μg / mL, respectively, and the enzyme-labeled secondary antibody was an anti-rabbit monoclonal antibody with a detectable marker.

[0167] After calculation, the optimal working concentration of gag3p is 5 μg / mL, and the optimal working concentration of gag3p-Mb is 1.6 μg / mL.

[0168] Example 3 Preparation of antigen pre-coated plate

[0169] The preparation method of the polystyrene microplate (ELISA plate) coated with the gag3p recombinant epitope protein is as follows:

[0170] Step 1: Add 5 μg / mL of gag3p recombinant epitope protein to a polystyrene microplate, 100 μL / well, shake and mix well, and incubate at 4°C overnight.

[0171] Step 2: Wash the plate with PBST, 200 μL / well, wash 3 times, and spin dry.

[0172] Step 3: Add 200 μL of 5% skim milk diluted with PBST to each well and incubate at room temperature for 1 h.

[0173] Step 4: Wash the plate with PBST, 200 μL / well, wash 3 times, spin dry, and seal with aluminum plastic film.

[0174] Example 4 Establishment of JSRV indirect competitive ELISA technology

[0175] (I) Animals used in the test kit

[0176] The test kit is mainly for sheep and goats, and can diagnose whether sheep and goats are suffering from OPA by detecting JSRV antigen in samples.

[0177] (II) Sample types and processing methods suitable for kit detection

[0178] (1) Nasal swab. Nasal swabs are collected by rotating a sterile cotton swab deep in the nasal cavity of sheep and goats. They contain nasal secretions from sheep and goats. Before testing, the nasal swab must be shaken in 1.0 mL of PBS to allow JSRV to dissolve in the liquid.

[0179] (2) Serum. Blood is collected aseptically from sheep and goats, and the serum collected by centrifugation after coagulation is used directly for testing.

[0180] (3) Pleural effusion and other secretions can be diluted with saline or used directly.

[0181] (III) Materials included in the kit

[0182] (1) Antigen pre-coated plate;

[0183] (2) Primary antibody: 1.6 μg / mL gag3p-Mb;

[0184] (3) Enzyme-labeled secondary antibody: anti-rabbit monoclonal antibody with a detectable marker;

[0185] (4) Substrate: TMB solution;

[0186] (5) Stop solution: 2.0 mol / L H2SO4 solution;

[0187] (6) Positive control;

[0188] (7) Negative control;

[0189] (8) Dilution plate;

[0190] (9) Antigen diluent: PBST;

[0191] (10) Sealing film.

[0192] (IV) Kit operation steps

[0193] (1) Add the sample to be tested to the dilution plate at 100 μL / well, then add the primary antibody at 100 μL / well, mix on a shaker for 10 min, seal the plate with a sealing film, and incubate at 37°C for 1 h.

[0194] (2) Add negative control to 2 wells of the ELISA reaction plate, 100 μL / well.

[0195] (3) Add positive control to 2 wells of the ELISA reaction plate, 100 μL / well.

[0196] (4) Add PBST (blank control) to one well of the ELISA reaction plate, 100 μL / well.

[0197] (5) Add the incubated sample to the detection wells of the ELISA reaction plate, 100 μL / well.

[0198] (6) Seal the plate with sealing film and incubate at 37°C for 1 h.

[0199] (7) Wash the plate with PBST (200 μL / well) for 3 times and spin dry. Wash the plate 3 times and spin dry.

[0200] (8) Add enzyme-labeled secondary antibody at 100 μL / well, seal the plate with sealing film, and incubate at 37°C for 1 h.

[0201] (9) Wash the plate with PBST (200 μL / well) for 3 times and spin dry. Wash the plate 3 times and spin dry.

[0202] (10) Add TMB substrate solution (100 μL / well), seal the plate with a sealing film, and develop the color at room temperature in the dark for 15 min.

[0203] (11) Add stop solution, 100 μL / well.

[0204] (12) OD 450 The value of each well was measured at a wavelength of nm.

[0205] (V) Result determination

[0206] Blocking rate calculation: PI = (1-P / N) × 100%, where:

[0207] Cut-off value = average PI value of positive control

[0208] If the PI of the sample to be tested is ≥ the critical value, it is judged as positive; otherwise, it is negative.

[0209] Example 5: Test kit related index verification

[0210] (I) Test kit detection compliance rate verification

[0211] 100 nasal swab samples positive for JSRV in an epidemiological survey stored in Yulin College, Yulin City, Shaanxi Province were taken and tested using the kit of the present invention and PCR technology respectively. The results showed that the consistency rate between the kit of the present invention and the PCR test results was 100%.

[0212] (II) Specificity

[0213] The kit of the present invention is used to detect sheep brucellosis, sheep dysentery, sheep enterotoxemia, sheep sudden death, sheep pox, peste des petits ruminants, O-type foot-and-mouth disease, sheep mycoplasma pneumonia and sheep endemic intranasal tumor virus (ENTV), respectively. The detection is repeated 3 times. The results show that the kit of the present invention can specifically detect the pathogen JSRV of OPA, but cannot detect sheep brucellosis, sheep dysentery, lamb dysentery, sheep enterotoxemia, sheep sudden death, sheep pox, peste des petits ruminants, O-type foot-and-mouth disease, sheep mycoplasma pneumonia and sheep endemic intranasal tumor virus (ENTV).

[0214] (III) Repeatability

[0215] The kit of the present invention is to take 2 kits from each of the 4 batches, and 8 known PCR positive samples are tested, and the average value of two replicates is taken to calculate the inter-batch variation coefficient CV = (SD / OD 450 nm average value)×100%, the results show that the kit of the present invention has good repeatability.

[0216] (IV) Sensitivity

[0217] On the basis of determining the JSRV virus titer in the sample by real-time fluorescence quantitative PCR, the JSRV sample was diluted at a ratio of 1:10, 1:50, 1:100, and 1:200, and the kit of the present invention was used for detection three times, and the average value was taken to determine the minimum detection amount of JSRV by the kit of the present invention. The minimum detection amount of JSRV by the kit of the present invention was 10 -2 copy.

[0218] It should be understood that the disclosed invention is not limited only to the specific method, scheme and material of description, because these all can change.It should also be understood that the terminology used herein is only for the purpose of describing specific embodiment scheme, rather than being intended to limit the scope of the present invention, and the scope of the present invention is only limited to the appended claims.

[0219] Those skilled in the art will also recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are also included in the appended claims. It should be noted that the various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments, and the same and similar parts between the various embodiments can be referred to each other.

[0220] Although the optional embodiments of the present invention have been described, those skilled in the art may make additional changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including optional embodiments and all changes and modifications that fall within the scope of the embodiments of the present invention.

[0221] Finally, it should be noted that, in the present invention, the terms "include", "comprises" or any other variants thereof are intended to cover non-exclusive inclusion, so that an article or terminal device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such article or terminal device. In the absence of further restrictions, the elements defined by the sentence "includes a ..." do not exclude the existence of other identical elements in the article or terminal device including the elements.

[0222] The technical solution provided by the present invention is introduced in detail above. Specific examples are used in this article to illustrate the principle and implementation mode of the present invention. At the same time, for those skilled in the art, according to the principle and implementation mode of the present invention, there will be changes in the specific implementation mode and application scope. In summary, the content of this specification should not be understood as limiting the present invention.

Claims

1. A gag recombinant epitope protein, characterized in that: The amino acid sequence of the gag recombinant epitope protein is: 1) as shown in SEQ ID NO: 1; or 2) A derivative amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence in 1), wherein the derivative amino acid sequence has the activity of the amino acid sequence shown in 1).

2. A polynucleotide, characterized in that The polynucleotide: a) encoding the gag recombinant epitope protein according to claim 1; b) as shown in SEQ ID NO:2; or c) is complementary to a) or b).

3. A polynucleotide construct, characterized in that The polynucleotide construct contains the polynucleotide according to claim 2.

4. A host cell, characterized in that The host cell contains the polynucleotide according to claim 2.

5. A composition for detecting JSRV, characterized in that The composition comprises the gag recombinant epitope protein according to claim 1, wherein the gag recombinant epitope protein is coated on a solid support, or the gag recombinant epitope protein carries a detectable marker.

6. A kit, characterized in that: The kit comprises the gag recombinant epitope protein according to claim 1.

7. The kit according to claim 6, characterized in that 1) The gag recombinant epitope protein is coated on a solid support; 2) the gag recombinant epitope protein carries a detectable marker; or 3) The gag recombinant epitope protein is not coated on a solid support and does not carry a detectable marker.

8. A kit for detecting JSRV, characterized in that: The kit comprises: A solid support coated with a gag recombinant epitope protein, Rabbit polyclonal antibody against gag recombinant epitope protein, Anti-rabbit monoclonal antibody with detectable label.

9. Use of the gag recombinant epitope protein according to claim 1 in preparing a composition for detecting JSRV or a kit for detecting JSRV.

10. Use of the composition according to claim 5 or the kit according to claim 8 in detecting JSRV.